Myungin Pharm

At a glance

Myungin Pharm filed 27 disclosures in the last 12 months, including 3 insider, 1 earnings and 1 5% holder. The most recent key filing was on Jul 31.

Revenue for 2025 was ₩287B, up 6.6% on 2024. Operating margin was 32.2% against 34.4% a year earlier. Debt was 6% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩148B and operating profit of ₩52.7B.

The 2025 annual report lists 532 employees with an average tenure of 9.1 years and average pay of ₩78.7M, #398 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩233M each on average. It paid ₩1,500 per common share in cash dividends, against ₩1,000 a year earlier (+50%). 이행명 and related parties held 73.80% at year end.

From the 2025 annual report

Staff: 532 (440 men, 92 women), of whom 8 on fixed-term contracts. Total pay for the year: ₩42.1B. Directors and auditors: 6, paid ₩1.4B in total.

Dividends (common shares)

Largest shareholder

이행명 holds 50.88%; with 6 related parties the group holds 73.80% of common shares at year end (from 96.21% at the start of the year).

Individuals paid ₩500M or more

Auditor: 현대회계법인 · opinion: Unqualified.

Rankings: Low debt #8 of 1,372 · Operating margin #18 of 1,376

Source: 2025 annual business report (DART). How figures are combined

Financial summary